Table 5.
Drug susceptibility of P. kudriavzevii to non-azole antifungal drugs.
| Author | Year | MIC method | Anidulafungin | Caspofungin | Micafungin | Amphotericin B | Flucytosine |
|---|---|---|---|---|---|---|---|
| Arendrup27 | 2013 | EUCAST (EUCAST BP, CLSI BP for caspofungin and itraconazole) | (n = 52) 100% S |
(n = 25) 28% S |
ND | (n = 52) 73.1% S |
ND |
| Arikan-Akdagli75 | 2019 | CLSI | ND | ND | 0.08 (≤0.03-0.25), % S |
1.32 (0.5-2), 0% non-WT |
ND |
| Badiee19 | 2017 | CLSI (susceptibility based on CLSI BP, or ECV) | ND | 0.2 (0.032-2), 30% R |
ND | 1.004 (0.032-8), 40% R |
ND |
| Castanheira28 | 2020 | CLSI | 0% R | 0% R | 0% R | 0% non-WT | ND |
| Castanheira29 | 2014 | CLSI | 2.8% R | 2.8% R | 0% R | ND | ND |
| Castanheira24 | 2014 | CLSI | 0.03-1, 0.06, 0.12, 3.1% non-WT |
0.06-1, 0.12, 0.25, 3.1% non-WT |
0.015-0.12, 0.12, 0.12, 0% non-WT |
1-2,1,2,0% non-WT | 8-32, 16, 16, 0% non-WT |
| Chen77 | 2017 | Sensititre YeastOne | 0.12-0.25, 0.12, 0.12, 0% R 100% S |
0.25-0.5, 0.5, 0.5, 0% R, 23.1%S, 76.9% I |
0.6-0.12, 0.12, 0.12, 0% R, 100% S |
ND | ND |
| Fuller36 | 2019 | CLSI | ND | MIC not available, 0% R |
MIC not available, 0% R |
MIC not available, 100% WT (based on ECV ≤2) |
ND |
| Seyoum26 | 2020 | VITEK 2 compact system | ND | 0% R | 0% R | ND | 78.6% R |
| Hrabovsky79 | 2017 | EUCAST | 0.002-0.19, 0.008, 0.023,5% R |
0.002-0.25, 0.063,0.125, %R ND |
ND | 0.19-2, 0.5,1,5% R |
ND |
| Israel21 | 2019 | E-test (CLSI BP) | ND | 67% R | ND | 1.9% R | ND |
| Kaur12 | 2020 | CLSI | 0.28 (0.03-4), 0.12, 0.5 |
0.35 (0.12-2), 0.12, 0.5 |
0.45 (0.06-12), 0.12,0.5 |
0.90 (0.25-2),1,1 | ND |
| Kaur23 | 2020 | CLSI | 1.9% R | 16% R | 2.5% R | 12.9% R | ND |
| Omrani14 | 2014 | CLSI | ND |
n = 6, 66.7% S |
ND |
n = 14, 100% S |
ND |
| Pfaller80 | 2011 | CLSI |
n = 16 ICU, 0% R, n = 20 non-ICU, 0% R |
n = 16 ICU, 6.3% R, n = 20 non-ICU, 5.0% R |
n = 16 ICU, 0% R, n = 20 non-ICU, 0% R |
ND | ND |
| Pfaller25 | 2015 | CLSI | 0% R, 100% S |
0% R, 100% S |
0% R, 100% S |
MIC/MEC range: 1-2, MIC50: 1, MIC90: 2,0% non-WT, 100% WT |
MIC/MEC range: 8-32, MIC50: 16, MIC90: 32, 0% non-WT, 100% WT |
| Salse81 | 2019 | E-test |
n = 117, mode MIC: 0.03 |
n = 565, mode MIC: 0.5 |
n = 259, mode MIC: 0.25 |
n = 534, mode MIC: 1 |
ND |
| Sasso37 | 2017 | E-test (CLSI BP) | ND | 62.6% S (n = 31) 86.8% I (n = 50) (averaged for 2007-2016) |
ND | 100% WT (n = 51) | ND |
| Tóth22 | 2019 | CLSI | 0.06 (0.015-0.25), 0.06, 0.12,100% S |
1 (0.12-1), 1,1,11.3% S, 22.6% I, 66.1% R |
0.25, (0.03-0.25), 0.25,0.25, 100% S |
1 (0.5-2),1,1 | ND |
Data are reported as they appear in source documents. Susceptibility is expressed as mg/l unless indicated otherwise.
BP=breakpoint, CLSI= Clinical and Laboratory Standards Institute, ECV=epidemiological cutoff value, EUCAST= European Committee on Antimicrobial Susceptibility Testing, R=resistant, S=susceptible, S-DD=susceptible dose-dependent, I=intermediate, ICU=intensive care unit, MIC= minimum inhibitory concentration, MEC=minimum effective concentration, GM= geometric mean, NA/ND= not applicable / not done, MIC50=MIC required to inhibit the growth of 50% of isolates, MIC90=MIC required to inhibit the growth of 90% of isolates, ND= no data, Non-WT = non wild-type.